Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 10/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | RARB | P10826 | 3/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7442187 | 1.00 | MGLL (0.43) | MGLLEGLN1FAAHCNR1RARB | |
| SCHEMBL7441259 | 0.89 | GCG (0.43) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7443933 | 0.89 | MGLL (0.45) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7441252 | 0.89 | GCG (0.43) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7443928 | 0.89 | MGLL (0.45) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7441281 | 0.88 | MGLL (0.46) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7448957 | 0.88 | ALDH1A1 (0.44) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7448955 | 0.88 | ALDH1A1 (0.44) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7441274 | 0.88 | MGLL (0.46) | MGLLFAAHCNR1RARBRARA | |
| SCHEMBL7440391 | 0.86 | GCG (0.47) | MGLLFAAHCNR1RARBRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6169103-B1 | FOR TREATMENT OF ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURISM, HEART FAILURE, ULCERS, CANCER, INFLAMMATION, PAIN, ARTHRITIS, OSTEOPOROSIS, AND OTHER AUTOIMMUNE OR INFLAMMATORY DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT | 2001-01-02 | — | — | US | claimed |
| US-6265432-B1 | CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT | 2001-07-24 | — | — | US | disclosed |
| US-6169103-B1 | FOR TREATMENT OF ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURISM, HEART FAILURE, ULCERS, CANCER, INFLAMMATION, PAIN, ARTHRITIS, OSTEOPOROSIS, AND OTHER AUTOIMMUNE OR INFLAMMATORY DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT | 2001-01-02 | — | — | US | disclosed |